Literature DB >> 656638

[Progressive pulmonary fibrosis during combination chemotherapy with BCNU (author's transl)].

W Schreml, G Bargon, B Anger, B Kubanek, H Heimpel.   

Abstract

In two patients with acute leukaemia, the development of progressive interstitial pulmonary fibrosis was observed following chemotherapy with BCNU, Cytoxan and Ara-C. The x-ray changes were accompanied by restrictive changes of pulmonary function and, later on, by severe hypoxia. Serologic tests did not reveal infection with cytomegaly virus or mycoplasma pneumoniae. These findings, together with reports in the literature, suggest a toxic effect of BCNU on the lung. The combination with Cyclophosphamide may contribute to this toxic reaction.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656638     DOI: 10.1007/BF01000593

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  5 in total

1.  Remission maintenance of acute nonlymphoblastic leukemia with BCNU (NSC-409962) and cyclophosphamide (NSC-26271).

Authors:  J Manaster; D H Cowan; J E Curtis; R Hasselback; D E Bergsagel
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

2.  Pulmonary toxicity in long-term administration of BCNU.

Authors:  P Y Holoye; D E Jenkins; S D Greenberg
Journal:  Cancer Treat Rep       Date:  1976-11

3.  Triple combination chemotherapy of disseminated melanoma.

Authors:  S M Cohen; E M Greenspan; M J Weiner; B Kabakow
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

Review 4.  The spectrum of drug-induced pulmonary disease.

Authors:  E C Rosenow
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

5.  [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].

Authors:  U R Kleeberg; W Schreml
Journal:  Dtsch Med Wochenschr       Date:  1976-06-04       Impact factor: 0.628

  5 in total
  1 in total

Review 1.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.